Join the 200th Anniversary Celebration

Original Article

Mutations in the Mu Heavy-Chain Gene in Patients with Agammaglobulinemia

Leman Yel, M.D., Yoshiyuki Minegishi, M.D., Elaine Coustan-Smith, M.Sc., Rebecca H. Buckley, M.D., Hubert Trübel, M.D., Lauren M. Pachman, M.D., Geoffrey R. Kitchingman, Ph.D., Dario Campana, M.D., Ph.D., Jurg Rohrer, Ph.D., and Mary Ellen Conley, M.D.

N Engl J Med 1996; 335:1486-1493November 14, 1996

Abstract

Background

Most patients with congenital hypogammaglobulinemia and absent B cells are males with X-linked agammaglobulinemia, which is caused by mutations in the gene for Bruton's tyrosine kinase (Btk); however, there are females with a similar disorder who do not have mutations in this gene. We studied two families with autosomal recessive defects in B-cell development and patients with presumed X-linked agammaglobulinemia who did not have mutations in Btk.

Methods

A series of candidate genes that encode proteins involved in B-cell signal-transduction pathways were analyzed by linkage studies and mutation screening.

Results

Four different mutations were identified in the mu heavy-chain gene on chromosome 14. In one family, there was a homozygous 75-to-100-kb deletion that included D-region genes, J-region genes, and the mu constant-region gene. In a second family, there was a homozygous base-pair substitution in the alternative splice site of the mu heavy-chain gene. This mutation would inhibit production of the membrane form of the mu chain and produce an amino acid substitution in the secreted form. In addition, a patient previously thought to have X-linked agammaglobulinemia was found to have an amino acid substitution on one chromosome at an invariant cysteine that is required for the intrachain disulfide bond and, on the other chromosome, a large deletion that included the immunoglobulin locus.

Conclusions

Defects in the mu heavy-chain gene are a cause of agammaglobulinemia in humans. This implies that an intact membrane-bound mu chain is essential for B-cell development.

Media in This Article

Figure 4Diagram of the Mu Heavy-Chain Gene Showing the Four Exons of the Cμ Constant-Region Domains and the Two Exons of the Membrane Domain.
Figure 5Evaluation of CD19+ Cells from the Bone Marrow of Patient 7 for the Expression of Terminal Deoxynucleotidyl Transferase (TdT) and Mu Heavy Chain.
Article

The development of B cells proceeds through a series of well-defined stages characterized by sequential rearrangements of immunoglobulin genes and by the expression and extinction of enzymes and structural proteins required for presentation of the immunoglobulin molecule on the cell surface and signal transduction through this molecule.1-3 Defects in B-cell development, both spontaneous defects in humans and those created by homologous recombination in mice, have clarified the importance of many of the genes involved in this process.

Patients with X-linked agammaglobulinemia have severe congenital hypogammaglobulinemia, and although they have normal numbers of pro-B cells, they have a marked reduction in the number of pre-B cells4 and less than 1 percent of the normal number of B cells.5 In 1993 two groups showed that X-linked agammaglobulinemia was caused by mutations in the gene for Bruton's tyrosine kinase (Btk), a cytoplasmic tyrosine kinase.6,7 The substrates phosphorylated by Btk have not yet been identified; however, it is clear that Btk is activated by cross-linking of a variety of cell-surface receptors, including, perhaps most importantly, surface IgM on B-lineage cells.8-11

Although over 100 different mutations in Btk have been identified, some patients with the clinical and laboratory characteristics of X-linked agammaglobulinemia have not demonstrated mutations in this gene.12-16 In addition, approximately 5 to 10 percent of patients with early-onset hypogammaglobulinemia and absent B cells are girls.17-20 Together, these findings suggest that there may be autosomal recessive disorders that are phenotypically identical to X-linked agammaglobulinemia. To investigate this possibility, we studied two consanguineous families in which both boys and girls had panhypogammaglobulinemia and markedly reduced numbers of B cells (Figure 1Figure 1Pedigrees of the Study Families.).

Methods

Patients

The members of Family A, who live in Appalachia, are of Scottish–Irish ancestry and have received their specialty medical care at Duke University Medical Center in Durham, North Carolina. Patient 1 was evaluated in 1973, at nine months of age, because of a six-week history of fever, weakness, and rashes. Immunologic studies showed hypogammaglobulinemia and absent B cells. He was given the diagnosis of X-linked agammaglobulinemia and treated with plasma therapy to provide gamma globulin. At 4 1/2 years of age, he died of chronic enteroviral encephalitis. Patient 2, a cousin of Patient 1, had bilateral pneumonia at four months of age and was evaluated in 1979 at six months of age, when she had persistent infection and failure to thrive. Laboratory studies demonstrated hypogammaglobulinemia and reduced numbers of B cells, but normal cellular immunity. Chronic enteroviral encephalitis developed, and the girl was treated with high-dose intravenous immune globulin and a course of intrathecal immune globulin, which resulted in the resolution of most signs of infection at six years of age. She is currently receiving intravenous immune globulin and is doing well, with mild mental retardation. (Patients 1 and 2 have been previously described as Patients 22 and 25 by McKinney et al.18) Patient 3, a nephew of Patient 1, had chronic otitis and had an episode of bronchopneumonia and gastroenteritis at seven months of age. In 1991, at one year of age, he was evaluated for recurrent infections and was found to have hypogammaglobulinemia. He has done well since that time with intravenous immune globulin treatment. Patient 4, the brother of Patient 3, was examined at one month of age in 1991 because of the family history of immunodeficiency. Treatment with intravenous immune globulin was begun when he was found to have hypogammaglobulinemia. He has not had noteworthy infections.

The members of Family B are of Turkish descent and have received their specialty care at Mainz University Hospital in Mainz, Germany. Recurrent respiratory tract infections developed in Patient 5 at three months of age. At seven months of age, in 1993, he was hospitalized for septic shock due to Pseudomonas aeruginosa. He was found to have hypogammaglobulinemia and absent B cells, and he was treated with intravenous immune globulin and given the diagnosis of X-linked agammaglobulinemia. Since that time he has done well, except for an episode of aseptic arthritis at two years of age. Patient 6, the sister of Patient 5, was hospitalized in 1994, at six months of age, with pneumonia. She was recognized to have hypogammaglobulinemia, and treatment with intravenous immune globulin was begun. She has had recurrent episodes of perirectal abscesses.

Patient 7 is the son of a Korean mother and a white father, born in 1983. At 15 months of age, two weeks after he had received oral poliovirus vaccine, fevers, weakness, rashes, and neutropenia developed. At 20 months of age, he was hospitalized at Children's Memorial Hospital, Chicago, for persistent fevers and weakness. He was found to have hypogammaglobulinemia and absent B cells, and treatment with intravenous immune globulin was begun. Although he has some residual weakness and recurrent otitis, he has had normal growth and development.

Polymerase Chain Reaction

Genomic DNA was isolated from peripheral-blood leukocytes. The polymerase chain reaction (PCR) was carried out in a 20-μl volume containing 100 ng of genomic DNA, 100 μM of each deoxynucleotide triphosphate, 20 pmol of each primer, and 1 U of Taq DNA polymerase. For single-strand conformation polymorphism (SSCP) analysis, 3 μCi of [32P]α-deoxycytidine triphosphate was added to the reaction mix. The samples were denatured at 95°C for 5 minutes, followed by 30 cycles at 95°C for 45 seconds and annealing at the temperature indicated in Table 1Table 1Primer Pairs Used to Screen Genomic DNA for Mutations in the Mu Heavy-Chain Gene. for 30 seconds and at 72°C for 30 seconds, with a final 5-minute extension at 72°C.

Single-Strand Conformation Polymorphism

SSCP analysis was performed as previously described,12 except that some PCR samples were digested with restriction enzymes before analysis. Labeled amplified DNA was mixed with loading buffer (95 percent formamide, 20 nM EDTA, 0.05 percent bromophenol blue, and 0.05 percent xylene cyanole FF) in a 1:5 ratio, denatured for five minutes at 90°C, placed on ice, loaded onto an MDE gel (AT Biochem, Malvern, Pa.), and electrophoresed at 4°C in 0.6× TBE buffer (1× TBE buffer is 89 mM TRIS, 89 mM borate, and 2 mM EDTA) at 2 to 4 W overnight. Gels were transferred to 3MM paper (Whatman, Clifton, N.J.), dried, and exposed to Kodak X-OMAT film (Kodak, Rochester, N.Y.).

Short-Tandem-Repeat Analysis

The primer pairs for microsatellite-repeat polymorphisms near the genes for Syk (D9S257, D9S910, and D9S922), mb-1 (D19S178 and D19S246), and EBF (D5S1471, D5S820, and D5S1456) and the mu heavy-chain gene (D14S611 and D14S118) were obtained from Research Genetics (Huntsville, Ala.). PCR was used to amplify 32P-labeled DNA, which was analyzed on a denaturing 6 percent polyacrylamide gel.

Southern Blot Analysis

Standard methods were used in Southern blot analysis. The probes used to examine the genes for VH6 and JH4 and the constant-region genes for mu, delta, and gamma have been previously described.21-23 To obtain a probe for the DH region, a 500-bp PCR product based on the sequence reported by Ichihara et al.24 was produced with use of the forward primer 5'CAGGTACAGCTGTAGAGA3' and the reverse primer 5'AGACAGCAGCCTTGAGAG3'.

Cloning and Sequencing

PCR products from the patients with visible band shifts on SSCP analysis were cloned into TA vector (Invitrogen, San Diego, Calif.) and sequenced with use of M13 primers or oligonucleotides from the human mu heavy-chain gene. All mutations were confirmed by a second, independent PCR reaction.

Immunofluorescence Staining

Peripheral-blood lymphocytes were incubated with monoclonal anti-CD19 antibody and with goat antihuman IgM, both conjugated to phycoerythrin. Bone marrow cells were stained with anti-CD19, anti-CD34, and polyclonal antibodies against human light chains conjugated to phycoerythrin, peridinin chlorophyll protein, and fluorescein isothiocyanate, respectively. Nuclear terminal deoxynucleotidyl transferase (TdT) and cytoplasmic mu heavy chain were detected with specific antibodies conjugated to phycoerythrin and fluorescein isothiocyanate applied after cells had been rendered permeable with OrthoPermeafix (Ortho Diagnostics, Raritan, N.J.). Immunophenotypes were analyzed with a FACScan flow cytometer with Lysis II software (Becton Dickinson, San Jose, Calif.).

Results

Linkage Analysis

The patients in Family A were related through the maternal lineage; however, linkage analysis showed that the defect in this family did not map to the X-linked agammaglobulinemia locus at Xq22, and genomic DNA from Patient 2 did not demonstrate mutations in Btk. Therefore, a series of candidate genes that encode other proteins involved in signal transduction through the surface immunoglobulin receptor was chosen for analysis. Particular emphasis was placed on genes that are expressed early in B-cell differentiation and genes that are specific to the B-cell lineage. Linkage analysis was performed with highly polymorphic short tandem repeats located near the genes for Syk, a cytoplasmic tyrosine kinase encoded at 9q2225; CD79a (also known as mb-1 or Igα), an invariant component of the B-cell antigen–receptor complex that has been mapped to 19q13.226; EBF, a transcription factor required for CD79a transcription that is encoded at 5q3427; and the immunoglobulin heavy-chain genes at 14q32.3.28 The region showing the best linkage with the disease gene in Family A was near the immunoglobulin heavy-chain locus on the long arm of chromosome 14; when haplotypes derived from the polymorphisms at D14S611 and D14S118 were used, only a single crossover was seen. In Family B the parents shared a haplotype at this locus, and both children were homozygous for the shared haplotype.

Mutation Detection

A probe from the mu switch region, at the 5' end of the exons for the mu constant-region gene, cross-hybridizes to polymorphic switch regions at the 5' end of the genes for alpha 1 and alpha 2, revealing over 25 immunoglobulin haplotypes in genomic DNA digested with SacI. 29 This probe demonstrated complete linkage with the defect in Family A, an event that would be expected to occur by chance with a likelihood of less than 0.1 percent. The mu switch-region probe revealed a deletion in the affected children in Family B. The extent of this deletion was determined with probes for VH6, DK1, JH4, and the mu, delta, and gamma heavy-chain genes. A deletion of 75 to 100 kb, encompassing the D-region genes, the J-region genes, and the mu constant-region gene, including the membrane exons, was identified (Figure 2AFigure 2Southern Blot Analysis Demonstrating a Deletion That Includes the Mu Heavy-Chain Gene in Family B., Figure 2B, Figure 2C, Figure 2D). Using the signal intensity of the VH6 band to control for the amount of DNA loaded in each lane, we found that the signal intensity of the Cμ band in the DNA samples from the parents was approximately 50 percent of that of the control band.

To screen for mutations in the mu constant-region gene in Family A, PCR primers that flank each exon were designed for use in SSCP analysis (Table 1). Genomic DNA from the affected girl in Family A and from patients who were presumed to have X-linked agammaglobulinemia, but in whom mutations in Btk had not been identified, was screened. Analysis of exon 4, the exon that encodes the CH4 domain, demonstrated the loss of normal bands and the gain of different aberrant bands in the DNA from Patient 2 and from a boy with presumed X-linked agammaglobulinemia without a mutation in Btk (Patient 7) (Figure 3Figure 3SSCP Analysis and Sequencing of Exon 4 of the Cμ Gene, Demonstrating Mutations in DNA from Patients 2 and 7.). The loss of the normal bands suggested that the alterations in both patients were homozygous or hemizygous. The same primer pair, pair 4c, was used to examine DNA from 100 unrelated people (200 chromosomes) and did not demonstrate the pattern seen in either patient. All three affected children in Family A had the same aberrant pattern, and each family member who inherited the B haplotype (Figure 1) at the mu switch locus was heterozygous for the normal and the aberrant SSCP pattern.

DNA from both patients with altered band patterns in exon 4 was amplified by PCR, cloned, and sequenced. A single-base-pair substitution, a G-to-A transition at nucleotide 1831 (according to the numbering system of Friedlander et al.32), was found in the DNA of the affected girl. This alteration, which destroys an MspI restriction site, was confirmed in the DNA of Patients 2, 3, and 4 by digesting amplified DNA with this enzyme. This single-base-pair replacement is at the -1 position of the alternative splice-donor site that is used to produce the membrane rather than the secretory mu transcript (Figure 4Figure 4Diagram of the Mu Heavy-Chain Gene Showing the Four Exons of the Cμ Constant-Region Domains and the Two Exons of the Membrane Domain.). A mutation at this critical site would be expected to have three effects. First, this change would cause a substitution of serine for glycine in the secreted form of the mu chain. Second, in the membrane form of the mu chain, a positively charged lysine would be substituted for the wild-type, negatively charged glutamic acid. Finally, because the alternative splice-donor site has only weak homology to the consensus splice-donor sequence (Shapiro–Senapathy score, 71.5),33 the loss of the consensus G at the -1 position would be expected to markedly reduce efficient splicing at this site, leading to an absence of the membrane form of the mu heavy chain.

The DNA from Patient 7 showed a T-to-G transition at nucleotide 1768 (Figure 4); this alteration, which creates an MspI restriction site, was confirmed by digesting PCR-amplified DNA with this enzyme. This nucleotide change results in the substitution of glycine for the wild-type cysteine at codon 536 in the carboxy-terminal immunoglobulin domain of the mu chain.34 The cysteine at this site is the 3' cysteine involved in the intrachain disulfide bridge that is characteristic of all immunoglobulin domains.35 This mutation would be expected to result in an unstable form of both membrane and secreted mu chain.36 To determine whether Patient 7 was homozygous or hemizygous for this mutation, his genomic DNA was digested with SacI and examined by Southern blot analysis with a probe for the mu constant-region gene. A single fragment of the expected size was detected; however, the intensity of the signal was 50 percent of that of the control, suggesting a deletion of the mu-chain gene on one chromosome. Further studies using the VH6 probe and a probe for the gamma constant-region genes also showed a 50 percent decrease in signal intensity, indicating that the deletion was greater than 260 kb. The karyotype was normal.

Functional Studies

To determine the physiologic consequences of mutations in the mu-chain gene, we compared the phenotype of peripheral-blood lymphocytes from Patients 2, 3, 4, and 7 with those from patients with known mutations in Btk. The number of CD19+ B cells, as determined by flow cytometry, was markedly decreased in patients with mutations in Btk; however, 38 of 44 patients had detectable B cells (between 0.01 and 1.0 percent of peripheral-blood lymphocytes5). By contrast, none of the patients with mutations in the mu-chain gene had detectable B cells (less than 0.01 percent of peripheral-blood lymphocytes).

Bone marrow was obtained from Patient 7 to determine the point in B-cell differentiation at which maturation was blocked. The results demonstrated that the patient had normal percentages of the earliest precursors, pro-B cells that express CD19 and CD34 on the cell surface and terminal deoxynucleotidyl transferase in the nucleus. However, there was a marked decrease in the number of cells at the next stage in B-cell differentiation, the stage at which mu heavy chain is first expressed in the cytoplasm (Figure 5Figure 5Evaluation of CD19+ Cells from the Bone Marrow of Patient 7 for the Expression of Terminal Deoxynucleotidyl Transferase (TdT) and Mu Heavy Chain.). There was a small number of IgM-positive cells, but the staining for IgM was dim (the mean fluorescence intensity for IgM was 34.65 in Patient 7, as compared with 120.35 in the control), a finding consistent with the hypothesis that the amino acid substitution in the mu heavy chain in Patient 7 resulted in an unstable protein.

Discussion

Many proteins are required for the assembly and expression of the immunoglobulin molecule; however, it is the mu heavy-chain gene itself that is at the center of this process. Our studies show that several different types of mutations in this gene are a cause of profound immunodeficiency in humans. Homologous recombination has been used to “knock out” the J-region genes or the membrane exons of the mu-chain gene in murine models of immunodeficiency.37-39 In contrast to alterations in Btk, which result in a mild B-cell abnormality in mice,40-42 but a much more severe defect in humans,4,5 the B-cell phenotype of mice that have mutations in the mu constant-region gene is identical to that of patients with mutations in this gene. In both there is a complete absence of B-cell production and profound hypogammaglobulinemia.

Heterozygous deletions of the mu heavy-chain gene have been reported in two patients with complex chromosomal rearrangements involving chromosome 14.28 These patients had multiple morphologic defects but no immunodeficiency. It is notable that the heterozygous parents, siblings, and aunts and uncles included in our study were also free of immunodeficiency. Deletions of the gamma, alpha, or epsilon heavy-chain gene, or of a combination of these genes, have been described by several groups.43 Persons with these deletions have subclass deficiencies but usually have minimal or no signs of immunodeficiency.

The two families in this study represent the only families that we have analyzed in which both males and females have lacked B cells. Although we have identified mutations in either the mu heavy-chain gene or Btk in 79 unrelated persons referred for genetic analysis, we have also studied an additional 4 patients with sporadic disease who did not have mutations in either gene. This suggests that the immunodeficiency in these patients is due to a combination of genetic and environmental factors or that there may be additional forms of autosomal recessive disease resulting in the absence of B cells.

The identification of genes that cause immunodeficiencies has both clinical and biologic implications. As improved therapies for immunodeficiencies become available, it may be critical to know the exact nature of the genetic defect. Specific mutations also provide clues to the normal development of the B-cell lineage. The findings in our patients support the hypothesis that expression of a surface mu chain is essential for the progression of B-cell differentiation beyond the pre-B-cell stage.

Supported in part by grants from the National Institutes of Health (AI25129, CA58297, PO1 CA20180, and P30 CA21765) and Duke University (CRU-MOI-RR-30) and by the American Lebanese Syrian Associated Charities and the Federal Express Chair of Excellence.

We are indebted to the study families for their willingness to participate in these studies, to Jason E. Farrar for excellent technical assistance, and to Janice Mann for help in the preparation of the manuscript.

Source Information

From the Departments of Immunology (L.Y., Y.M., J.R., M.E.C.), Hematology/Oncology (E.C.-S., D.C.), and Virology (G.R.K.), St. Jude Children's Research Hospital, Memphis, Tenn.; the Department of Pediatrics, Duke University School of Medicine, Durham, N.C. (R.H.B.); the Department of Pediatrics, University of Mainz, Mainz, Germany (H.T.); the Department of Pediatrics, Northwestern University Medical School, Chicago (L.M.P.); and the Department of Pediatrics, University of Tennessee, Memphis (L.Y., D.C., M.E.C.).

Address reprint requests to Dr. Conley at St. Jude Children's Research Hospital, 332 North Lauderdale, Memphis, TN 38105.

References

References

  1. 1

    Burrows PD, Cooper MD. Regulated expression of cell surface antigens during B cell development. Semin Immunol 1990;2:189-195
    Medline

  2. 2

    Melchers F, Haasner D, Grawunder U, et al. Roles of IgH and L chains and of surrogate H and L chains in the development of cells of the B lymphocyte lineage. Annu Rev Immunol 1994;12:209-225
    CrossRef | Web of Science | Medline

  3. 3

    Satterthwaite A, Witte O. Genetic analysis of tyrosine kinase function in B cell development. Annu Rev Immunol 1996;14:131-154
    CrossRef | Web of Science | Medline

  4. 4

    Campana D, Farrant J, Inamdar N, Webster ADB, Janossy G. Phenotypic features and proliferative activity of B cell progenitors in X-linked agammaglobulinemia. J Immunol 1990;145:1675-1680
    Web of Science | Medline

  5. 5

    Conley ME. B cells in patients with X-linked agammaglobulinemia. J Immunol 1985;134:3070-3074
    Web of Science | Medline

  6. 6

    Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993;72:279-290
    CrossRef | Web of Science | Medline

  7. 7

    Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361:226-233[Erratum, Nature 1993;364:362.]
    CrossRef | Web of Science | Medline

  8. 8

    de Weers M, Brouns GS, Hinshelwood S, et al. B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J Biol Chem 1994;269:23857-23860
    Web of Science | Medline

  9. 9

    Aoki Y, Isselbacher KJ, Pillai S. Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. Proc Natl Acad Sci U S A 1994;91:10606-10609
    CrossRef | Web of Science | Medline

  10. 10

    Saouaf SJ, Mahajan S, Rowley RB, et al. Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement. Proc Natl Acad Sci U S A 1994;91:9524-9528
    CrossRef | Web of Science | Medline

  11. 11

    Kawakami Y, Yao L, Miura T, Tsukada S, Witte ON, Kawakami T. Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon FcεRI cross-linking. Mol Cell Biol 1994;14:5108-5113
    Web of Science | Medline

  12. 12

    Conley ME, Fitch-Hilgenberg ME, Cleveland JL, Parolini O, Rohrer J. Screening of genomic DNA to identify mutations in the gene for Bruton's tyrosine kinase. Hum Mol Genet 1994;3:1751-1756
    CrossRef | Web of Science | Medline

  13. 13

    Bradley LAD, Sweatman AK, Lovering RC, et al. Mutation detection in the X-linked agammaglobulinemia gene, BTK, using single strand conformation polymorphism analysis. Hum Mol Genet 1994;3:79-83
    CrossRef | Web of Science | Medline

  14. 14

    Hagemann TL, Chen Y, Rosen FS, Kwan SP. Genomic organization of the Btk gene and exon scanning for mutations in patients with X-linked agammaglobulinemia. Hum Mol Genet 1994;3:1743-1749
    CrossRef | Web of Science | Medline

  15. 15

    Vorechovsky I, Vihinen M, de Saint Basile G, et al. DNA-based mutation analysis of Bruton's tyrosine kinase gene in patients with X-linked agammaglobulinaemia. Hum Mol Genet 1995;4:51-58
    CrossRef | Web of Science | Medline

  16. 16

    Jin H, Webster ADB, Vihinen M, et al. Identification of Btk mutations in 20 unrelated patients with X-linked agammaglobulinaemia (XLA). Hum Mol Genet 1995;4:693-700
    CrossRef | Web of Science | Medline

  17. 17

    Hoffman T, Winchester R, Schulkind M, Frias JL, Ayoub EM, Good RA. Hypoimmunoglobulinemia with normal T cell function in female siblings. Clin Immunol Immunopathol 1977;7:364-371
    CrossRef | Medline

  18. 18

    McKinney RE Jr, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis 1987;9:334-356
    CrossRef | Medline

  19. 19

    Conley ME, Sweinberg SK. Females with a disorder phenotypically identical to X-linked agammaglobulinemia. J Clin Immunol 1992;12:139-143
    CrossRef | Web of Science | Medline

  20. 20

    de La Morena M, Haire RN, Ohta Y, et al. Predominance of sterile immunoglobulin transcripts in a female phenotypically resembling Bruton's agammaglobulinemia. Eur J Immunol 1995;25:809-815
    CrossRef | Web of Science | Medline

  21. 21

    Borzillo GV, Cooper MD, Kubagawa H, Landay A, Burrows PD. Isotype switching in human B lymphocyte malignancies occurs by DNA deletion: evidence for nonspecific switch recombination. J Immunol 1987;139:1326-1335
    Web of Science | Medline

  22. 22

    Borzillo GV, Cooper MD, Bertoli LF, Landay A, Castleberry R, Burrows PD. Lineage and stage specificity of isotype switching in humans. J Immunol 1988;141:3625-3633
    Web of Science | Medline

  23. 23

    Carter M, Neale GA, Kitchingman GR. Characterization of immunoglobulin heavy chain genes from an acute lymphocytic leukemia with four rearrangements. Leukemia 1991;5:668-672
    Web of Science | Medline

  24. 24

    Ichihara Y, Matsuoka H, Kurosawa Y. Organization of human immunoglobulin heavy chain diversity gene loci. EMBO J 1988;7:4141-4150
    Web of Science | Medline

  25. 25

    Ku G, Malissen B, Mattei MG. Chromosomal location of the Syk and ZAP-70 tyrosine kinase genes in mice and humans. Immunogenetics 1994;40:300-302
    CrossRef | Web of Science | Medline

  26. 26

    Ha H, Barnoski BL, Sun L, Emanuel BS, Burrows PD. Structure, chromosomal localization, and methylation pattern of the human mb-1 gene. J Immunol 1994;152:5749-5757
    Web of Science | Medline

  27. 27

    Milatovich A, Qiu RG, Grosschedl R, Francke U. Gene for a tissue-specific transcriptional activator (EBF or Olf-1), expressed in early B lymphocytes, adipocytes, and olfactory neurons, is located on human chromosome 5, band q34, and proximal mouse chromosome 11. Mamm Genome 1994;5:211-215
    CrossRef | Web of Science | Medline

  28. 28

    Benger JC, Teshima I, Walter MA, Brubacher MG, Daouk GH, Cox DW. Localization and genetic linkage of the human immunoglobulin heavy chain genes and the creatine kinase brain (CKB) gene: identification of a hot spot for recombination. Genomics 1991;9:614-622
    CrossRef | Web of Science | Medline

  29. 29

    Migone N, Fede J, Cann H, et al. Multiple DNA fragment polymorphisms associated with immunoglobulin mu chain switch-like regions in man. Proc Natl Acad Sci U S A 1983;80:467-471
    CrossRef | Web of Science | Medline

  30. 30

    Nagaoka H, Ozawa K, Matsuda F, et al. Recent translocation of variable and diversity segments of the human immunoglobulin heavy chain from chromosome 14 to chromosomes 15 and 16. Genomics 1994;22:189-197
    CrossRef | Web of Science | Medline

  31. 31

    Benger JC, Cox DW. Polymorphisms of the immunoglobulin heavy-chain delta gene and association with other constant-region genes. Am J Hum Genet 1989;45:606-614
    Web of Science | Medline

  32. 32

    Friedlander RM, Nussenzweig MC, Leder P. Complete nucleotide sequence of the membrane form of the human IgM heavy chain. Nucleic Acids Res 1990;18:4278-4278
    CrossRef | Web of Science | Medline

  33. 33

    Shapiro MB, Senapathy P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 1987;15:7155-7174
    CrossRef | Web of Science | Medline

  34. 34

    Putnam FW, Florent G, Paul C, Shinoda T, Shimizu A. Complete amino acid sequence of the Mu heavy chain of a human IgM immunoglobulin. Science 1973;182:287-291
    CrossRef | Web of Science | Medline

  35. 35

    Beale D, Feinstein A. Structure and function of the constant regions of immunoglobulins. Q Rev Biophys 1976;9:135-180
    CrossRef | Web of Science | Medline

  36. 36

    Bubb MO, Conradie JD. Studies on the structural and biological functions of the Cμ3 and Cμ4 domains of IgM. Immunology 1978;34:449-458
    Web of Science | Medline

  37. 37

    Kitamura D, Roes J, Kuhn R, Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991;350:423-426
    CrossRef | Web of Science | Medline

  38. 38

    Gu H, Zou YR, Rajewsky K. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 1993;73:1155-1164
    CrossRef | Web of Science | Medline

  39. 39

    Chen J, Trounstine M, Alt FW, et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int Immunol 1993;5:647-656
    CrossRef | Web of Science | Medline

  40. 40

    Thomas JD, Sideras P, Smith CIE, Vorechovsky I, Chapman V, Paul WE. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 1993;261:355-358
    CrossRef | Web of Science | Medline

  41. 41

    Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 1993;261:358-361
    CrossRef | Web of Science | Medline

  42. 42

    Wicker LS, Scher I. X-linked immune deficiency (xid) of CBA/N mice. Curr Top Microbiol Immunol 1986;124:87-101
    CrossRef | Web of Science | Medline

  43. 43

    Smith CIE, Islam KB, Vorechovsky I, et al. X-linked agammaglobulinemia and other immunoglobulin deficiencies. Immunol Rev 1994;138:159-183
    CrossRef | Web of Science | Medline

Citing Articles (75)

Citing Articles

  1. 1

    Pheidias C. Wu, Jiun-Bo Chen, Shoji Kawamura, Christian Roos, Stefan Merker, Chih-Chin Shih, Ban-Dar Hsu, Carmay Lim, Tse Wen Chang. (2011) The IgE gene in primates exhibits extraordinary evolutionary diversity. Immunogenetics
    CrossRef

  2. 2

    Mirjam Burg, Menno C. Zelm, Gertjan J. A. Driessen, Jacques J. M. Dongen. (2011) New frontiers of primary antibody deficiencies. Cellular and Molecular Life Sciences
    CrossRef

  3. 3

    Jan E. Slotta, Sabine Heine, Anne Kauffels, Thomas Krenn, Frank Grünhage, Mathias Wagner, Norbert Graf, Martin K. Schilling, Jochen Schuld. (2011) Gastrectomy with isoperistaltic jejunal parallel pouch in a 15-year-old adolescent boy with gastric adenocarcinoma and autosomal recessive agammaglobulinemia. Journal of Pediatric Surgery 46:9, e21-e24
    CrossRef

  4. 4

    A. K. Dobbs, A. Bosompem, E. Coustan-Smith, G. Tyerman, F. T. Saulsbury, M. E. Conley. (2011) Agammaglobulinemia associated with BCR- B cells and enhanced expression of CD19. Blood 118:7, 1828-1837
    CrossRef

  5. 5

    D. Corcos, M. J. Osborn, L. S. Matheson. (2011) B-cell receptors and heavy chain diseases: guilty by association?. Blood 117:26, 6991-6998
    CrossRef

  6. 6

    M. Mendicino, J. Ramsoondar, C. Phelps, T. Vaught, S. Ball, T. LeRoith, J. Monahan, S. Chen, A. Dandro, J. Boone, P. Jobst, A. Vance, N. Wertz, Z. Bergman, X-Z. Sun, I. Polejaeva, J. Butler, Y. Dai, D. Ayares, K. Wells. (2011) Generation of antibody- and B cell-deficient pigs by targeted disruption of the J-region gene segment of the heavy chain locus. Transgenic Research 20:3, 625-641
    CrossRef

  7. 7

    M. C. van Zelm, J. Smet, M. van der Burg, A. Ferster, P. Q. Le, L. Schandene, J. J. M. van Dongen, F. Mascart. (2011) Antibody deficiency due to a missense mutation in CD19 demonstrates the importance of the conserved tryptophan 41 in immunoglobulin superfamily domain formation. Human Molecular Genetics 20:9, 1854-1863
    CrossRef

  8. 8

    Eline T. Luning Prak, Jacqueline Ross, Jennifer Sutter, Kathleen E. Sullivan. (2011) Age-Related Trends in Pediatric B-Cell Subsets. Pediatric and Developmental Pathology 14:1, 45-52
    CrossRef

  9. 9

    Andre M. Vale, Harry W. Schroeder. (2010) Clinical consequences of defects in B-cell development. Journal of Allergy and Clinical Immunology 125:4, 778-787
    CrossRef

  10. 10

    D. G. Paige, A. R. Gennery, A. J. Cant. 2010. The Neonate. , 1-85.
    CrossRef

  11. 11

    Alain Fischer. 2010. The Immunocompromised Host. .
    CrossRef

  12. 12

    Taco W. Kuijpers, Richard J. Bende, Paul A. Baars, Annette Grummels, Ingrid A.M. Derks, Koert M. Dolman, Tim Beaumont, Thomas F. Tedder, Carel J.M. van Noesel, Eric Eldering, René A.W. van Lier. (2010) CD20 deficiency in humans results in impaired T cell–independent antibody responses. Journal of Clinical Investigation 120:1, 214-222
    CrossRef

  13. 13

    Mary Ellen Conley, A. Kerry Dobbs, Dana M. Farmer, Sebnem Kilic, Kenneth Paris, Sofia Grigoriadou, Elaine Coustan-Smith, Vanessa Howard, Dario Campana. (2009) Primary B Cell Immunodeficiencies: Comparisons and Contrasts. Annual Review of Immunology 27:1, 199-227
    CrossRef

  14. 14

    Yoshimi Kuroiwa, Poothappillai Kasinathan, Thillainayagen Sathiyaseelan, Jin-an Jiao, Hiroaki Matsushita, Janaki Sathiyaseelan, Hua Wu, Jenny Mellquist, Melissa Hammitt, Julie Koster, Satoru Kamoda, Katsumi Tachibana, Isao Ishida, James M Robl. (2009) Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Nature Biotechnology 27:2, 173-181
    CrossRef

  15. 15

    Nima Rezaei, Kasra Moazzami, Asghar Aghamohammadi, Christoph Klein. (2009) Neutropenia and Primary Immunodeficiency Diseases. International Reviews of Immunology 28:5, 335-366
    CrossRef

  16. 16

    Y. Minegishi, H. Karasuyama. (2008) Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. International Immunology 21:2, 105-112
    CrossRef

  17. 17

    Vassilios Lougaris, Simona Ferrari, Alessandro Plebani. (2008) Igβ deficiency in humans. Current Opinion in Allergy and Clinical Immunology 8:6, 515-519
    CrossRef

  18. 18

    Patrick F.K. Yong, Ronnie Chee, Bodo Grimbacher. (2008) Hypogammaglobulinaemia. Immunology and Allergy Clinics of North America 28:4, 691-713
    CrossRef

  19. 19

    Vassilios Lougaris, Simona Ferrari, Marco Cattalini, Annarosa Soresina, Alessandro Plebani. (2008) Autosomal recessive agammaglobulinemia: Novel insights from mutations in Ig-beta. Current Allergy and Asthma Reports 8:5, 404-408
    CrossRef

  20. 20

    Menno C. van Zelm, Corinne Geertsema, Nicole Nieuwenhuis, Dick de Ridder, Mary Ellen Conley, Claudine Schiff, Ilhan Tezcan, Ewa Bernatowska, Nico G. Hartwig, Elisabeth A.M. Sanders, Jiri Litzman, Irina Kondratenko, Jacques J.M. van Dongen, Mirjam van der Burg. (2008) Gross Deletions Involving IGHM, BTK, or Artemis: A Model for Genomic Lesions Mediated by Transposable Elements. The American Journal of Human Genetics 82:2, 320-332
    CrossRef

  21. 21

    S. Ferrari, V. Lougaris, S. Caraffi, R. Zuntini, J. Yang, A. Soresina, A. Meini, G. Cazzola, C. Rossi, M. Reth, A. Plebani. (2007) Mutations of the Ig  gene cause agammaglobulinemia in man. Journal of Experimental Medicine 204:9, 2047-2051
    CrossRef

  22. 22

    Alejandro A Schäffer, Ulrich Salzer, Lennart Hammarström, Bodo Grimbacher. (2007) Deconstructing common variable immunodeficiency by genetic analysis. Current Opinion in Genetics & Development 17:3, 201-212
    CrossRef

  23. 23

    S Ferrari, R Zuntini, V Lougaris, A Soresina, V \[Sbreve]ourková, M Fiorini, S Martino, P Rossi, M C Pietrogrande, B Martire, G Spadaro, F Cardinale, F Cossu, P Pierani, I Quinti, C Rossi, A Plebani. (2007) Molecular analysis of the pre-BCR complex in a large cohort of patients affected by autosomal-recessive agammaglobulinemia. Genes and Immunity 8:4, 325-333
    CrossRef

  24. 24

    Hana Alachkar, Nadine Taubenheim, Mansel R. Haeney, Anne Durandy, Peter D. Arkwright. (2006) Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clinical Immunology 120:3, 310-318
    CrossRef

  25. 25

    van Zelm, Menno C., Reisli, Ismail, van der Burg, Mirjam, Castaño, Diana, van Noesel, Carel J.M., van Tol, Maarten J.D., Woellner, Cristina, Grimbacher, Bodo, Patiño, Pablo J., van Dongen, Jacques J.M., Franco, José L., . (2006) An Antibody-Deficiency Syndrome Due to Mutations in the CD19 Gene. New England Journal of Medicine 354:18, 1901-1912
    Full Text

  26. 26

    Marion Espeli, Benjamin Rossi, Stéphane J.C. Mancini, Philippe Roche, Laurent Gauthier, Claudine Schiff. (2006) Initiation of pre-B cell receptor signaling: Common and distinctive features in human and mouse. Seminars in Immunology 18:1, 56-66
    CrossRef

  27. 27

    Rachel B. Gardner, Kelsey A. Hart, Tracy Stokol, Thomas J. Divers, M. Julia B.F. Flaminio. (2006) Fell Pony Syndrome in a Pony in North America. Journal of Veterinary Internal Medicine 20:1, 198-203
    CrossRef

  28. 28

    Asghar Aghamohammadi, Maurilia Fiorini, Mostafa Moin, Nima Parvaneh, Shahram Teimourian, Mehdi Yeganeh, Francesca Goffi, Hirokazu Kanegane, Ali Akbar Amirzargar, Zahra Pourpak, Nima Rezaei, Ali Salavati, Nima Pouladi, Sina Abdollahzade, Luigi D. Notarangelo, Toshio Miyawaki, Alessandro Plebani. (2006) Clinical, Immunological and Molecular Characteristics of 37 Iranian Patients with X-Linked Agammaglobulinemia. International Archives of Allergy and Immunology 141:4, 408-414
    CrossRef

  29. 29

    Charlotte Cunningham-Rundles, Prashant P. Ponda. (2005) Molecular defects in T- and B-cell primary immunodeficiency diseases. Nature Reviews Immunology 5:11, 880-892
    CrossRef

  30. 30

    Alessandra Pellegrini-Masini, Amy I. Bentz, Imogen C. Johns, Corrina S. Parsons, Jill Beech, Robert H. Whitlock, M. Julia B. F. Flaminio. (2005) Common variable immunodeficiency in three horses with presumptive bacterial meningitis. Journal of the American Veterinary Medical Association 227:1, 114-122
    CrossRef

  31. 31

    Francisco A. Bonilla, I. Leonard Bernstein, David A. Khan, Zuhair K. Ballas, Javier Chinen, Michael M. Frank, Lisa J. Kobrynski, Arnold I. Levinson, Bruce Mazer, Robert P. Nelson, Jordan S. Orange, John M. Routes, William T. Shearer, Ricardo U. Sorensen. (2005) Practice parameter for the diagnosis and management of primary immunodeficiency. Annals of Allergy, Asthma & Immunology 94:5, S1-S63
    CrossRef

  32. 32

    Mary Ellen Conley, Arnon Broides, Vivian Hernandez-Trujillo, Vanessa Howard, Hirokazu Kanegane, Toshio Miyawaki, Sheila A. Shurtleff. (2005) Genetic analysis of patients with defects in early B-cell development. Immunological Reviews 203:1, 216-234
    CrossRef

  33. 33

    Jennifer N. Wu, Gary A. Koretzky. (2004) The SLP-76 family of adapter proteins. Seminars in Immunology 16:6, 379-393
    CrossRef

  34. 34

    Bodo Grimbacher, Alejandro A. Schäffer, Hans-Hartmut Peter. (2004) The Genetics of Hypogammaglobulinemia. Current Allergy and Asthma Reports 4:5, 349-358
    CrossRef

  35. 35

    D. EASTWOOD, K. C. GILMOUR, K. NISTALA, C. MEANEY, H. CHAPEL, Z. SHERRELL, A. D. WEBSTER, E. G. DAVIES, A. JONES, H. B. GASPAR. (2004) Prevalence of SAP gene defects in male patients diagnosed with common variable immunodeficiency. Clinical and Experimental Immunology 137:3, 584-588
    CrossRef

  36. 36

    Megan S. Lim, Kojo S.J. Elenitoba-Johnson. (2004) The Molecular Pathology of Primary Immunodeficiencies. The Journal of Molecular Diagnostics 6:2, 59-83
    CrossRef

  37. 37

    V Moschese, P Orlandi, G Matteo, L Chini, R Carsetti, S Cesare, P Rossi. (2004) Insight into B cell development and differentiation. Acta Paediatrica 93, 48-51
    CrossRef

  38. 38

    Akihisa Sawada, Yoshihiro Takihara, Ji Yoo Kim, Yoshiko Matsuda-Hashii, Sadao Tokimasa, Hiroyuki Fujisaki, Keiko Kubota, Hiroko Endo, Takashi Onodera, Hideaki Ohta, Keiichi Ozono, Junichi Hara. (2003) A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans. Journal of Clinical Investigation 112:11, 1707-1713
    CrossRef

  39. 39

    T. Terada, H. Kaneko, T. Fukao, T. Teramoto, T. Asano, A. L. Li, K. Kasahara, N. Kondo. (2003) Semiquantitative Evaluation of mRNAs for the Membranous Form of Immunoglobulin Heavy Chain is Useful for Investigating the Etiology in CVID. Scandinavian Journal of Immunology 58:6, 649-654
    CrossRef

  40. 40

    Steven J Simonte, Charlotte Cunningham-Rundles. (2003) Update on primary immunodeficiency: defects of lymphocytes. Clinical Immunology 109:2, 109-118
    CrossRef

  41. 41

    W A Carrock Sewell, Matthew S Buckland, Stephen R A Jolles. (2003) Therapeutic Strategies in Common Variable Immunodeficiency. Drugs 63:13, 1359-1371
    CrossRef

  42. 42

    Mary Ellen Conley. (2002) Early defects in B cell development. Current Opinion in Allergy and Clinical Immunology 2:6, 517-522
    CrossRef

  43. 43

    M. Julia B. F. Flaminio, Veronique LaCombe, Catherine W. Kohn, Douglas F. Antczak. (2002) Common variable immunodeficiency in a horse. Journal of the American Veterinary Medical Association 221:9, 1296-1302
    CrossRef

  44. 44

    Eduardo Lopez Granados, Andrea S. Porpiglia, Mary Beth Hogan, Nuria Matamoros, Silvia Krasovec, Claudio Pignata, C.I.E. Smith, Lennart Hammarstrom, Janne Bjorkander, Bernd H. Belohradsky, G. Fontan Casariego, M.C. Garcia Rodriguez, Mary Ellen Conley. (2002) Clinical and molecular analysis of patients with defects in μ heavy chain gene. Journal of Clinical Investigation 110:7, 1029-1035
    CrossRef

  45. 45

    Mary E. Paul. (2002) Diagnosis of immunodeficiency: Clinical clues and diagnostic tests. Current Allergy and Asthma Reports 2:5, 349-355
    CrossRef

  46. 46

    Yue Wang, Hirokazu Kanegane, Ozden Sanal, Ilhan Tezcan, Fgen Ersoy, Takeshi Futatani, Toshio Miyawaki. (2002) NovelIg? (CD79a) gene mutation in a Turkish patient with B cell-deficient agammaglobulinemia. American Journal of Medical Genetics 108:4, 333-336
    CrossRef

  47. 47

    JEROEN G. NOORDZIJ, SANDRA DE BRUIN-VERSTEEG, W. MARIEKE COMANS-BITTER, NICO G. HARTWIG, RUDOLF W. HENDRIKS, RONALD DE GROOT, AND, JACQUES J.M. VAN DONGEN. (2002) Composition of Precursor B-Cell Compartment in Bone Marrow from Patients with X-Linked Agammaglobulinemia Compared with Healthy Children. Pediatric Research 51:2, 159-168
    CrossRef

  48. 48

    Eric Meffre, Michèle Milili, Carla Blanco-Betancourt, Henedina Antunes, Michel C. Nussenzweig, Claudine Schiff. (2001) Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. Journal of Clinical Investigation 108:6, 879-886
    CrossRef

  49. 49

    K. Agematsu, H. Nagumo, S. Hokibara, T. Mori, T. Wada, A. Yachie, H. Kanegane, T. Miyawaki, K. Sugita, H. Karasuyama, A. Komiyama. (2001) Complete arrest from pro- to pre-B cells in a case of B cell-negative severe combined immunodeficiency (SCID) without recombinase activating gene (RAG) mutations. Clinical and Experimental Immunology 124:3, 461-464
    CrossRef

  50. 50

    Alain Fischer. (2001) Primary immunodeficiency diseases: an experimental model for molecular medicine. The Lancet 357:9271, 1863-1869
    CrossRef

  51. 51

    G. P. Spickett. (2001) Current perspectives on common variable immunodeficiency (CVID). Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 31:4, 536-542
    CrossRef

  52. 52

    Irina Lehmann, M. Borte, U. Sack. (2001) Diagnostik von Immundefekten. Diagnosis of Immunodeficiencies. LaboratoriumsMedizin 25:11-12, 495-511
    CrossRef

  53. 53

    Hal M. Hoffman, John F. Bastian, Lynne M. Bird. (2001) Humoral immunodeficiency with facial dysmorphology and limb anomalies: a new syndrome. Clinical Dysmorphology 10:1, 1-8
    CrossRef

  54. 54

    Elisabeth E. Adderson, David H. Viskochil, John C. Carey, Ann O. Shigeoka, John C. Christenson, John F. Bohnsack, Harry R. Hill. (2000) Growth failure, intracranial calcifications, acquired pancytopenia, and unusual humoral immunodeficiency: A genetic syndrome?. American Journal of Medical Genetics 95:1, 17-20
    CrossRef

  55. 55

    Mackay, Ian R., Rosen, Fred S., , Buckley, Rebecca H., . (2000) Primary Immunodeficiency Diseases Due to Defects in Lymphocytes. New England Journal of Medicine 343:18, 1313-1324
    Full Text

  56. 56

    Beichu Guo, Roberta M Kato, Maria Garcia-Lloret, Matthew I Wahl, David J Rawlings. (2000) Engagement of the Human Pre-B Cell Receptor Generates a Lipid Raft–Dependent Calcium Signaling Complex. Immunity 13:2, 243-253
    CrossRef

  57. 57

    H. Kanegane, S. Tsukada, T. Iwata, T. Futatani, K. Nomura, J. Yamamoto, T. Yoshida, K. Agematsu, A. Komiyama, T. Miyawaki. (2000) Detection of Bruton's tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry. Clinical and Experimental Immunology 120:3, 512-517
    CrossRef

  58. 58

    W Davis. (2000) Flow cytometric analysis of an immunodeficiency disorder affecting juvenile llamas. Veterinary Immunology and Immunopathology 74:1-2, 103-120
    CrossRef

  59. 59

    H. B. Gaspar, M. E. Conley. (2000) IMMUNODEFICIENCY REVIEWEarly B cell defects. Clinical and Experimental Immunology 119:3, 383-389
    CrossRef

  60. 60

    Yoshiyuki Minegishi, Jurg Rohrer, Mary Ellen Conley. (1999) Recent progress in the diagnosis and treatment of patients with defects in early B-cell development. Current Opinion in Pediatrics 11:6, 528-532
    CrossRef

  61. 61

    Leo D. Wang, Marcus R. Clark. (1999) Igα: B all that you can B. Journal of Clinical Investigation 104:8, 1011-1012
    CrossRef

  62. 62

    Yoshiyuki Minegishi, Elaine Coustan-Smith, Lisa Rapalus, Fügen Ersoy, Dario Campana, Mary Ellen Conley. (1999) Mutations in Igα (CD79a) result in a complete block in B-cell development. Journal of Clinical Investigation 104:8, 1115-1121
    CrossRef

  63. 63

    Srish Sinha, Seth J. Corey. (1999) Implications for Src Kinases in Hematopoiesis: Signal Transduction Therapeutics. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 8:5, 465-480
    CrossRef

  64. 64

    Mary Ellen Conley. (1999) Genetic effects on immunity New genes — how do they fit?. Current Opinion in Immunology 11:4, 427-430
    CrossRef

  65. 65

    ALEXANDER R. LAWTON. (1999) IgG subclass deficiency and the day-care generation. The Pediatric Infectious Disease Journal 18:5, 462-466
    CrossRef

  66. 66

    Pierre Quartier, Marianne Debré, Jacques De Blic, Rodolphe de Sauverzac, Natacha Sayegh, Nada Jabado, Elie Haddad, Stéphane Blanche, Jean-Laurent Casanova, C.I. Edvard Smith, Françoise Le Deist, Geneviève de Saint Basile, Alain Fischer. (1999) Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients. The Journal of Pediatrics 134:5, 589-596
    CrossRef

  67. 67

    Fred Gilbert. (1999) Chromosome 14. Genetic Testing 3:4, 379-391
    CrossRef

  68. 68

    Mary Ellen Conley, Max D Cooper. (1998) Genetic basis of abnormal B cell development. Current Opinion in Immunology 10:4, 399-406
    CrossRef

  69. 69

    Mary Ellen Conley, Derrick Mathias, Jason Treadaway, Yoshiyuki Minegishi, Jurg Rohrer. (1998) Mutations in Btk in Patients with Presumed X-Linked Agammaglobulinemia. The American Journal of Human Genetics 62:5, 1034-1043
    CrossRef

  70. 70

    C. I. Edvard Smith, Carl-Magnus Bckesj, Anna Berglf, Lars J. Brandn, Tahmina Islam, Pekka T. Mattsson, Abdalla J. Mohamed, Susanne Mller, Beston Nore, Mauno Vihinen. (1998) X-linked agammaglobulinemia: lack of mature B lineage cells caused by mutations in the Btk kinase. Springer Seminars in Immunopathology 19:4, 369-381
    CrossRef

  71. 71

    Anna Berglöf, Karin Sandstedt, Ricardo Feinstein, Göran Bölske, C. I. Edvard Smith. (1997) B cell-deficient μMT mice as an experimental model forMycoplasma infections in X-linked agammaglobulinemia. European Journal of Immunology 27:8, 2118-2121
    CrossRef

  72. 72

    Gavin P. Spickett, John Farrant, Margaret E. North, Jiang-gang Zhang, Lynn Morgan, A. David B. Webster. (1997) Common variable immunodeficiency: how many diseases?. Immunology Today 18:7, 325-328
    CrossRef

  73. 73

    E Meffre, F LeDeist, G de Saint-Basile, A Deville, M Fougereau, A Fischer, C Schiff. (1997) A non-XLA primary deficiency causes the earliest known defect of B cell differentiation in humans: a comparison with an XLA case. Immunology Letters 57:1-3, 93-99
    CrossRef

  74. 74

    Peter D Burrows, Max D Cooper. (1997) B cell development and differentiation. Current Opinion in Immunology 9:2, 239-244
    CrossRef

  75. 75

    Manis, John, , Schwartz, Robert S., . (1996) Agammaglobulinemia and Insights into B-Cell Differentiation. New England Journal of Medicine 335:20, 1523-1525
    Full Text